Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, has received the European CE Mark for MPX(TM), the company's high-powered, dual-wavelength aesthetic workstation to liquefy fat and tighten skin through collagen remodeling. The CE Mark certifies that the MPX conforms to the essential health and safety requirements of the European Medical Device Directive.

Cynosure expects to launch MPX through its subsidiaries in the European Union beginning this quarter. Cynosure has marketed and sold MPX in the United States since the second quarter of 2008.

"The quality associated with the MPX brand is an important differentiator for Cynosure among U.S. customers and consumers, and we expect this to be equally true as we introduce MPX to the international market," said President and Chief Executive Officer Michael Davin. "We believe the integration of our MultiPlex(TM) technology and SmartSense(TM) intelligent delivery system makes MPX the ideal platform blending body sculpting and tissue tightening through coagulation. Together, these applications are forecast to help drive the global aesthetic market from $8.4 billion in 2007 to more than $15 billion by 2011(1). We expect that our continued focus on innovation will enable Cynosure to remain at the forefront of this high-growth market."

"The EU represents the next phase of our multi-pronged strategy to expand the geographic reach of our MPX technology," Davin said. "MPX training for our European subsidiaries is already underway, and they are eager to introduce the product in their markets. This rollout will be followed by a targeted launch in select countries in the Middle East, as well as ongoing submissions for regulatory approvals in the Asia Pacific region."